THERAVANCE BIOPHARMA INC's ticker is TBPH and the CUSIP is G8807B106. A total of 89 filers reported holding THERAVANCE BIOPHARMA INC in Q2 2018. The put-call ratio across all filers is 0.22 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2019 | $57,000 | -10.9% | 2,500 | 0.0% | 0.00% | 0.0% |
| Q4 2018 | $64,000 | -22.0% | 2,500 | 0.0% | 0.00% | 0.0% |
| Q3 2018 | $82,000 | +43.9% | 2,500 | 0.0% | 0.00% | 0.0% |
| Q2 2018 | $57,000 | -6.6% | 2,500 | 0.0% | 0.00% | 0.0% |
| Q1 2018 | $61,000 | -12.9% | 2,500 | 0.0% | 0.00% | 0.0% |
| Q4 2017 | $70,000 | -18.6% | 2,500 | 0.0% | 0.00% | 0.0% |
| Q3 2017 | $86,000 | -14.0% | 2,500 | 0.0% | 0.00% | 0.0% |
| Q2 2017 | $100,000 | – | 2,500 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Madison Avenue Partners, LP | 7,269,584 | $69,497,223,000 | 12.98% |
| Newtyn Management, LLC | 1,375,000 | $13,145,000 | 3.15% |
| Chescapmanager LLC | 1,166,574 | $11,152,000 | 1.51% |
| Baupost Group | 13,643,333 | $130,430,000 | 1.40% |
| Weiss Asset Management LP | 5,412,487 | $51,743,000 | 1.07% |
| CM Management, LLC | 120,000 | $1,147,000 | 0.96% |
| Orbimed Advisors | 3,254,713 | $31,115,000 | 0.50% |
| King Wealth Management Group | 122,000 | $1,166,000 | 0.23% |
| Woodline Partners LP | 1,326,653 | $12,683,000 | 0.21% |
| PDT Partners, LLC | 192,701 | $1,842,000 | 0.16% |